73 terminated. 73 Phase 2, 9 Phase 1, 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 73 | Terminated 73 |
| Phase 1 | 9 | Terminated 9 |
| Phase 3 | 7 | Terminated 7 |
Follow Mouth Diseases: new trials by email Literature Review of Mouth Diseases trials Research Report on Mouth Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome HZN-1116, Placebo - Sjogren's Syndrome | Phase 2 | Terminated | Amgen | 209 | 2024-05-09 | 2026-05-08 |
| A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery Near Infrared Imaging, Therapeutic Conventional Surgery, Tozuleristide - Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8 | Phase 1 / Phase 2 | Terminated | University of Washington | 8 | 2024-04-17 | 2026-09-16 |
| Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant Xylitol, Placebo - Allogeneic Stem Cell Transplantation | Phase 2 | Terminated | Children's Hospital Medical Center, Cincinnati | 256 | 2023-04-04 | 2026-09-28 |
| A Study of NTX-001 in the Treatment and Prevention of Facial Paralysis Requiring Surgical Repair. NTX-001 - Facial Paralysis | Phase 2 | Terminated | Neuraptive Therapeutics Inc. | 2 | 2022-07-12 | 2023-09-11 |
| Erenumab-aooe for the Management of Trigeminal Neuropathic Pain. Erenumab-Aooe, Placebo - Trigeminal Neuropathy | Phase 2 | Terminated | University of Maryland, Baltimore | 5 | 2022-05-31 | 2024-03-22 |
| A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD) MHV370, Placebo - Sjogren Syndrome, Mixed Connective Tissue Disease | Phase 2 | Terminated | Novartis Pharmaceuticals | 30 | 2021-11-30 | 2024-10-09 |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Alectinib - Neoplasms, Colorectal Neoplasms | Phase 2 | Terminated | Hoffmann-La Roche | 1 | 2021-05-24 | 2023-08-07 |
| Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer. Clonidine HCl Mucoadhesive Buccal Tablet, Placebo Mucoadhesive Buccal Tablet - Chemoradiotherapy-Induced Severe Oral Mucositis | Phase 2 / Phase 3 | Terminated | Monopar Therapeutics | 190 | 2021-02-11 | 2023-05-31 |
| A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS) GLPG3970, Placebo - Primary Sjögren Syndrome | Phase 2 | Terminated | Lakefront Biotherapeutics NV | 31 | 2021-01-28 | 2023-09-18 |
| A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease Hemay005, Placebo - Behçet Disease | Phase 2 | Terminated | Tianjin Hemay Pharmaceutical Co., Ltd | 89 | 2020-11-30 | 2022-06-21 |
| Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection HDIT101 (blinded therapy), Placebo (blinded therapy), Photo documentation of orolabial herpes lesions - Herpes Labialis | Phase 2 | Terminated | Heidelberg ImmunoTherapeutics GmbH | 761 | 2020-10-08 | 2023-09-25 |
| Golimumab for the Treatment of Refractory Behcet's Uveitis Golimumab (GOL) - Behcet Syndrome, Uveitis | Phase 2 | Terminated | Wenjie Zheng | 1 | 2020-02-15 | 2023-04-07 |
| Serum-derived Bovine Immunoglobulin Effect on Mucositis SBI, Placebo - Mucositis | Phase 2 | Terminated | MercyOne Des Moines Medical Center | 10 | 2020-01-17 | 2023-01-26 |
| Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer Celecoxib, Placebo, Quality-of-Life Assessment - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Terminated | University of Utah | 13 | 2019-11-27 | 2025-02-12 |
| Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - Pediatric Kovanaze Nasal Spray, Articaine Injection - Caries,Dental, Apical Periodontitis | Phase 2 | Terminated | Virginia Commonwealth University | 3 | 2019-08-28 | 2020-11-19 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome Remibrutinib, Placebo - Sjögren Syndrome | Phase 2 | Terminated | Novartis Pharmaceuticals | 73 | 2019-07-12 | 2023-01-30 |
| Trial for Treatment Refractory Trigeminal Neuralgia Rimegepant, Placebo - Trigeminal Neuralgia | Phase 2 | Terminated | Pfizer | 65 | 2019-06-25 | 2024-06-10 |
| Cabozantinib in Advanced Salivary Gland Cancer Patients Cabozantinib - Salivary Gland Cancer | Phase 2 | Terminated | Radboud University Medical Center | 25 | 2018-09-05 | 2021-03-12 |
| ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment Laboratory Biomarker Analysis, Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet, Pharmacological Study - Oral Cavity Neoplasm, Oropharyngeal Neoplasm | Phase 2 | Terminated | National Cancer Institute (NCI) | 6 | 2018-05-31 | 2023-03-08 |
| Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis Oral Defense Toothpaste, Crest Toothpaste, Magic Mouth Rinse - Mucositis, Neoplasms | Phase 2 | Terminated | Oral Defense, LLC | 1 | 2018-05-29 | 2019-02-06 |
Showing 20 of 73. Sign in to see all of them.
Head and Neck Neoplasms (14) · Mouth Neoplasms (14) · Squamous Cell Carcinoma of Head and Neck (13) · Mucositis (11) · Salivary Gland Neoplasms (9) · Sjogren's Syndrome (8) · Stomatitis (7) · Xerostomia (7) · Oropharyngeal Neoplasms (6) · Laryngeal Neoplasms (5) · Neoplasms (5) · Autoimmune Diseases (4) · Behcet Syndrome (4) · Carcinoma, Squamous Cell (4) · Tongue Neoplasms (4)
Stomatognathic Diseases (72) · Neoplasms (31) · Neoplasms by Site (31) · Salivary Gland Diseases (21) · Skin and Connective Tissue Diseases (21) · Neoplasms by Histologic Type (19) · Neoplasms, Glandular and Epithelial (18) · Carcinoma (17) · Head and Neck Neoplasms (17) · Skin Diseases (14) · Mouth Neoplasms (13) · Immune System Diseases (12) · Digestive System Diseases (11) · Eye Diseases (11)
Cisplatin (6) · Radiotherapy (4) · Surgical Procedures, Operative (4) · Docetaxel (3) · Fluorouracil (3) · Radiation (3) · Amifostine (2) · Celecoxib (2) · Cetuximab (2) · Everolimus (2) · Saline Solution (2) · tocilizumab (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 1-phenyl-3,3-dimethyltriazene (1) · Acetylcysteine (1)
National Cancer Institute (NCI) (5) · Emory University (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · National Institute of Dental and Craniofacial Research (NIDCR) (2) · National Institute of Nursing Research (NINR) (2) · Novartis Pharmaceuticals (2) · Roswell Park Cancer Institute (2) · Sesen Bio, Inc. (2) · University College, London (2) · Wenjie Zheng (2) · Abramson Cancer Center at Penn Medicine (1) · Amgen (1) · Amy Beres (1) · Azienda USL 4 Prato (1) · Brett King (1)
United States (51) · Germany (11) · United Kingdom (7) · China (6) · Italy (6) · France (5) · Hungary (5) · Poland (5) · Spain (5) · Canada (4) · Australia (3) · Mexico (3) · Taiwan (3) · Argentina (2) · Austria (2)
Wendy Cuthbert (2) · Wenjie Zheng, M.D. (2) · Alan Joslyn, Ph.D. (1) · Anurag Singh (1) · Arvind Chaudhry, MD,PhD (1) · Athanassios Argiris, MD (1) · Barbara A. Murphy, MD (1) · Carla ML van Herpen, MD, PhD (1) · Catherine Vincent (1) · Chris Boshoff (1) · Christopher Dandoy, MD, MSc (1) · Dhimant Patel, MD (1)
PMID 16760642, PMID 18155609, PMID 18164921, PMID 21477333, PMID 23000649, PMID 23881549, PMID 24114811, PMID 27986347, PMID 28528519, PMID 29471416, PMID 31308059, PMID 34920917, PMID 36220750, PMID 37932009, PMID 37939426, PMID 38949635, PMID 39584361, PMID 40747756, PMID 40787733, PMID 41748391
1UG3DE030401-01 (1), 2008 (1), 2016 (1), 2018 (1), N01CM00032 (1), N01CN00033 (1), N01CN35153 (1), N01CN35159 (1), P30CA006516 (1), P30CA014520 (1), P30CA016056 (1), P30CA016672 (1), P30CA042014 (1), U10CA032102 (1), U10CA037429 (1)